menu
    • menu
    [{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Sofpironium Bromide","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Botanix Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"","sponsorNew":"Botanix Pharma \/ Botanix Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Botanix Pharma \/ Botanix Pharma"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Botanix Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Botanix Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Botanix Pharma

    Menu

    Botanix Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Botanix Pharma

    Australia arrow
    BePharma
    Not Confirmed

    Botanix Pharma

    Australia arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sofpironium Bromide

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    No sweat for dermatology specialist Botanix as hyperhidrosis gel Sofdra gains FDA approval

    Details : Sofdra (sofpironium) works by inhibiting M3 muscarinic receptors in eccrine glands. It is approved for the treatment of primary axillary hyperhidrosis in patients ages 9 and older.

    Product Name : Sofdra

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 20, 2024

    Lead Product(s) : Sofpironium Bromide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Botanix Pharma

    Australia arrow
    BePharma
    Not Confirmed

    Botanix Pharma

    Australia arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sofpironium Bromide

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Recipient : Fresh Tracks Therapeutics

    Deal Size : $8.2 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Fresh Tracks Announces $8.25 Million Buyout of its Right to Receive Future Sofpironium Bromide Payments from B...

    Details : Under the agreement, Fresh Tracks provided consulting services as an independent contractor to Botanix in support of and through filing and approval of the U.S. new drug application for BBI-4000 (sofpironium bromide gel).

    Product Name : BBI-4000

    Product Type : Small molecule

    Upfront Cash : $8.2 million

    July 21, 2023

    Lead Product(s) : Sofpironium Bromide

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Recipient : Fresh Tracks Therapeutics

    Deal Size : $8.2 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth